|
Market Closed -
Toronto S.E.
22:35:56 10/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.4500 CAD | -2.17% |
|
-5.26% | -1.10% |
| 08-27 | Pharmacorp Rx Inc. Announces Board and Committee Changes, Effective from August 31, 2026 | CI |
| 08-20 | PharmaCorp Rx Swings to Q2 Profit as Revenue Jumps | MT |
Company Valuation: PharmaCorp Rx Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 63.34 | 75.95 | 78.34 | - | - |
| Change | - | 19.91% | 3.14% | - | - |
| Enterprise Value (EV) 1 | 63.34 | 53.55 | 84.94 | 85.79 | 82.71 |
| Change | - | -15.46% | 58.63% | 1% | -3.59% |
| P/E | -54x | -45.5x | 45x | 15x | - |
| PBR | - | - | - | - | - |
| PEG | - | - | -0x | 0x | - |
| Capitalization / Revenue | - | 3.64x | 1.55x | 0.8x | 0.92x |
| EV / Revenue | - | 2.56x | 1.68x | 0.87x | 0.97x |
| EV / EBITDA | - | 15.2x | 20.9x | 8.08x | 7.36x |
| EV / EBIT | - | - | 49.1x | 13.2x | 22.1x |
| EV / FCF | - | 27.9x | -69.2x | 16.4x | 11.3x |
| FCF Yield | - | 3.58% | -1.45% | 6.09% | 8.86% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.01 | -0.01 | 0.01 | 0.03 | - |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 20.89 | 50.61 | 98.12 | 85.37 |
| EBITDA 1 | - | 3.528 | 4.061 | 10.62 | 11.24 |
| EBIT 1 | - | - | 1.731 | 6.508 | 3.737 |
| Net income 1 | -1.013 | -1.481 | 1.5 | 6.7 | - |
| Net Debt 1 | - | -22.4 | 6.603 | 7.451 | 4.371 |
| Reference price 2 | 0.5400 | 0.4550 | 0.4500 | 0.4500 | 0.4500 |
| Nbr of stocks (in thousands) | 117,296 | 166,927 | 174,082 | - | - |
| Announcement Date | 4/22/25 A | 4/29/26 A | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 46x | 1.71x | 21.34x | - | 57.97M | |
| 16.08x | 0.63x | 9.38x | -.--% | 14.34B | |
| 16.37x | 0.73x | 7.65x | 2.27% | 6.48B | |
| 20.28x | 0.76x | 12.85x | 1.1% | 6.29B | |
| 14.64x | 0.9x | 6.2x | 2.87% | 4.12B | |
| 14.45x | 1.24x | 7.59x | 5.57% | 3.22B | |
| 14.02x | 0.59x | 4.57x | 5.15% | 3.1B | |
| 13.24x | 0.79x | 5.91x | 4.91% | 2.78B | |
| 35.35x | - | - | - | 2.75B | |
| Average | 21.16x | 0.92x | 9.44x | 3.12% | 4.79B | |
| Weighted average by Cap. | 17.41x | 0.75x | 8.58x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCRX Stock
- Valuation PharmaCorp Rx Inc.
Select your edition
All financial news and data tailored to specific country editions
